Siponimod (BAF-312)
1230487-00-9
≥98%
516
1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid; 3-Azetidinecarboxylic acid, 1-((4-((1E)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)
- Data sheet: View or download
- MSDS: View or download
Siponimod is an orally bioavailable agonist of the sphingosine-1-phosphate (S1P) receptor that is selective for S1P1 and S1P5 with EC₅₀ values of 0.39 and 0.98 nM respectively, in a GTPγS-binding assay. Siponimod (0.3 or 3 mg/kg/day mg/kg/day) reduces experimental autoimmune encephalomyelitis (EAE) symptoms in rats. It significantly attenuates demyelination in organotypic cerebellar slice cultures. It is used for the treatment of relapsing forms of multiple sclerosis.
-20°C
